Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX

Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vac...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2004-06, Vol.22 (17), p.2103-2105
Main Author: Kitchener, Scott
Format: Article
Language:English
Subjects:
Applied microbiology
Arboviroses
Biological and medical sciences
Encephalitis
Encephalomyelitis, Acute Disseminated - epidemiology
Europe
Fever
Fundamental and applied biological sciences. Psychology
Hepatitis
Human viral diseases
Humans
Immunization
Incidence
Infectious diseases
Medical sciences
Microbiology
Multiple Organ Failure - epidemiology
Neurotropic disease
Poliomyelitis
Tetanus
Tropical diseases
Tropical viral diseases
Vaccination
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Attenuated - administration & dosage
Vaccines, Attenuated - adverse effects
Vector-borne diseases
Viral diseases
Viral Vaccines - administration & dosage
Viral Vaccines - adverse effects
Viscerotropic disease
Yellow fever
Yellow Fever - prevention & control
Yellow fever vaccine
Yellow Fever Vaccine - administration & dosage
Yellow Fever Vaccine - adverse effects
Yellow fever virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX™, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX™. Similar incidence data is required from other countries for comparison.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2004.01.026